Lenvatinib and tislelizumab versus atezolizumab and bevacizumab in combination with TAE-HAIC for unresectable hepatocellular carcinoma with high tumor burden: a multicenter retrospective cohort study
TAE-HAIC plus lenvatinib and tislelizumab or TAE-HAIC plus atezolizumab and bevacizumab showed similar outcomes for unresectable HCC with high tumor burden, and manageable safety. The results need further validation.
Authors
- Zhiqiang Wu (ORCID: https://orcid.org/0000-0002-1800-9527)
- Shuang‐Yan Tang (ORCID: https://orcid.org/0000-0002-1056-8690)
- Hongjie Cai (ORCID: https://orcid.org/0000-0001-9666-3172)
- Yi Xiao (ORCID: https://orcid.org/0000-0001-5315-7771)
- Song Chen (ORCID: https://orcid.org/0000-0002-2339-3471)
- Wenbo Guo (ORCID: https://orcid.org/0000-0002-1017-4640)
- Feng Shi (ORCID: https://orcid.org/0000-0003-3509-3473)
- Ping Ma (ORCID: https://orcid.org/0000-0001-6241-336X)
- Wenquan Zhuang (ORCID: https://orcid.org/0000-0002-6384-2489)
- Huanwei Chen (ORCID: https://orcid.org/0000-0001-9080-6435)
Institutions
- Sun Yat-sen University (CN)
- First People's Hospital of Foshan (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Twelfth Guangzhou City People's Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Guangdong Provincial People's Hospital (CN)
- Eighth Affiliated Hospital of Sun Yat-sen University
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1007/s00262-025-03942-3
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.64